News | September 10, 2025
Navin Fluorine inaugurates Phase-1 of new cGMP-4 facility of Navin Molecular at Devas
The cGMP-4 facility will further strengthen the company's ability to serve global partners
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
Contracts are related to a $487 million biotech expansion project in Denmark and first phase of a new life sciences production facility valued at $574 million in Central U.S.
Fluorouracil Injection is indicated for the treatment of patients with adenocarcinoma of colon and rectum and breast
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Construction is now underway with the facility scheduled to be operational by 2025
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Speakers for the Session are: Venkata Prasad K., Unit Head, Deepak Nitrite; Abhilash Pasham, Associate General Manager - Central Engineering & Projects, Dr. Reddy's Laboratories; C. V. Rajulu, Consultant, Industry; and Jyoti Shankar Jha, Senior Lead Scientist, Alleima India. The moderator for the Session is Pravin Prashant, Executive Editor, Indian Pharma Post
Subscribe To Our Newsletter & Stay Updated
